Dogan NO, et al. – Researchers assessed the efficacy and safety of intravenous metoclopramide treatment for acute migraine in this this double-blind, randomized, parallel-group, placebo-controlled trial that included 148 participants. Following assessment for eligibility using the International Headache Society criteria for migraines, study participants were randomized to receive either 10-mg intravenous metoclopramide or normal saline. Headache intensity was evaluated via an 11-point numeric rating scale score. The primary outcome was defined as the median between-group change in the score at the 30th minute. Secondary outcome measures included rescue medication needs, adverse events, and emergency department revisits post-discharge. Overall, they did not observe any differences between intravenous metoclopramide and placebo regarding their effectiveness and safety for acute migraine treatment. No serious adverse events were reported, and the rescue medication needs were similar across groups.